Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Mobocertinib in Hepatic Impairment
NCT04056468Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Oct 2020
- Primary completion
- Feb 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of mobocertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration, Maximum Observed Unbound Plasma Concentration and 6 more. Started Oct 2020; status: completed.
02
Drugs
mobocertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04056468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04056468.